Full-Time

Manager – Document Quality & Compliance of Medical Writing Delivery & Excellence

Updated on 3/26/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

No salary listed

Senior, Expert

London, UK + 1 more

More locations: Oxford, UK

This role is expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Editing & Proofreading
Technical Writing
Content & Writing
Medical, Clinical & Veterinary
Requirements
  • Advanced degree (preferred) with approximately 3 years of relevant experience OR bachelor’s degree with approximately 8 years of relevant experience.
  • Ability to exchange complex information with others in difficult situations.
  • Ability to mentor junior members of the team (if applicable).
  • Understanding of how own team integrates with others in accomplishing medical writing objectives.
  • Committed to quality with high attention to detail, organizational skills, and the ability to manage multiple tasks simultaneously.
  • Strong understanding of the technical aspects of the job. Proficiency in the use of standard industry software and tools (including Veeva).
Responsibilities
  • Develop and implement departmental strategies, setting goals and objectives for the Medical Writing Delivery & Excellence team in alignment with Moderna’s overarching business strategy.
  • Oversee medical writing documentation and processes to ensure compliance with regulatory, industry, and corporate standards.
  • Support cross-functional communication, internal and external resourcing, and quality control processes for clinical and regulatory documents.
  • Design and enhance tools aligned with standardized templates and style guides to improve efficiency and document consistency across the team.
  • Provide training and mentorship to team members, fostering a culture of excellence and continuous improvement.
  • Engage in cross-functional collaboration, ensuring that Medical Writing Delivery & Excellence’s outputs align with broader business objectives.
  • Solve complex problems by identifying and selecting appropriate solutions, leveraging technical expertise and industry best practices.
  • Contribute to the team's overall efficiency and effectiveness by setting clear performance expectations and handling sensitive issues with professionalism.
  • Stay current on regulatory requirements and medical writing best practices to ensure Moderna’s documentation remains inspection-ready.
  • Support process improvements and change management initiatives within the Medical Writing and Clinical Trial Transparency functions.
  • Drive the adoption of digital tools to enhance efficiency and streamline medical writing operations, including Veeva and other industry-standard platforms.
  • Ensure that documentation workflows are aligned with Moderna’s high standards of quality and compliance.
Desired Qualifications
  • Advanced degree (preferred)

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it leverages the body's own processes to generate therapeutic proteins. Moderna aims to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna plans to launch a cancer vaccine with Merck by 2027.
  • The company secured a $590 million contract for bird flu vaccine development.
  • Moderna's mRNA COVID-19 vaccine supply agreement with the EU spans four years.

What critics are saying

  • Moderna faces a high-profile patent lawsuit with Pfizer and BioNTech.
  • The company reported significant net losses in 2024, impacting financial stability.
  • Regulatory scrutiny may delay product approvals, affecting future growth.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company focuses on mRNA technology for personalized medicine and vaccines.
  • Moderna's mRNA platform enables rapid development of therapeutics and vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.

Bloomberg
Mar 5th, 2025
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck

Moderna Inc. expects to launch a personalized cancer vaccine that it's developing with Merck & Co. by 2027, one of its top executives said.

The Wall Street Journal
Feb 27th, 2025
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract

Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.

Financial Modeling Prep
Feb 14th, 2025
Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.

PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S